Skip to main content Back to Top
Advertisement

11/8/2019

Levetiracetam Extended-Release Tablets

Products Affected - Description

    • Levetiracetam oral extended release tablet, Apotex, 500 mg, bottle, 60 count, NDC 60505-3280-06
    • Levetiracetam oral extended release tablet, Apotex, 750 mg, bottle, 60 count, NDC 60505-3517-06
    • Levetiracetam oral extended release tablet, Lupin, 500 mg, bottle, 60 count, NDC 68180-0117-07
    • Levetiracetam oral extended release tablet, Lupin, 750 mg, bottle, 60 count, NDC 68180-0118-07
    • Levetiracetam oral extended release tablet, Sun Pharma, 500 mg, bottle, 60 count, NDC 47335-0573-86
    • Levetiracetam oral extended release tablet, Sun Pharma, 750 mg, bottle, 60 count, NDC 47335-0576-86

Reason for the Shortage

    • Lupin did not provide a reason for the shortage.
    • OWP is discontinuing their Roweepra XR formulations.
    • Sun Pharma did not provide a reason for the shortage.
    • Torrent is not selling their levetiracetam extended-release tablets within the US.

Available Products

    • Keppra XR oral extended release tablet, UCB, 500 mg, bottle, 60 count, NDC 50474-0598-66
    • Keppra XR oral extended release tablet, UCB, 750 mg, bottle, 60 count, NDC 50474-0599-66

Estimated Resupply Dates

    • Apotex has levetiracetam extended-release 500 mg and 750 mg tablets on allocation.
    • Lupin has levetiracetam extended-release 500 mg tablets on intermittent back order and the company is releasing product as it becomes available. The 750 mg extended-release tablets are on allocation.
    • Sun Pharma has levetiracetam extended-release 500 mg and 750 mg tablets on intermittent back order and the company is shipping product as it becomes available.

Updated

Updated November 8, 2019 by Anthony Trovato, PharmD, BCPS. Created August 6, 2019 by Anthony Trovato, PharmD, BCPS. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins